Nordic Pharma Introduces LACRIFILL Canalicular Gel for Dry Eye at AAO 2024 Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is showcasing LACRIFILL Canalicular Gel, a novel therapy for dry eye, at the American Academy of Ophthalmology (AAO) 2024.…
Wisp Expands Menopause Solutions and Launches Weight Care Vertical for Women Wisp, the leading women’s telehealth company in the U.S. dedicated to sexual and reproductive health, has announced a significant expansion of its services to better support women throughout their…
GE HealthCare Unveils Hospital Pulse Tile for Command Center Software GE HealthCare (Nasdaq: GEHC) has announced the launch of Hospital Pulse, a new tile within its Command Center Software Platform. This innovative feature consolidates real-time information from various departments into…
Charles River Laboratories International, Inc. (NYSE: CRL) has launched the Retrogenix® Non-Human Protein Library, a first-in-class in vitro tool designed to help biopharmaceutical clients assess off-target binding within a non-human proteome. This innovative library aims to de-risk in vivo studies…
1910 Genetics Launches CANDID-CNS™, an AI Model for Blood-Brain Barrier Permeability Prediction 1910 Genetics, a biotechnology company specializing in small and large molecule drug discovery, has announced the launch of CANDID-CNS™, an AI model designed to predict blood-brain barrier (BBB)…
Alterome Therapeutics, Inc. Recognized at Goldman Sachs Builders and Innovators Summit Alterome Therapeutics, Inc., a biopharmaceutical company specializing in next-generation small molecule targeted therapies for cancer, announced that Eric Murphy, Ph.D., CEO and co-founder, was honored as one of the…
iProov Reports 63% Transaction Growth Amid Rising Demand for Biometric Solutions iProov, a leader in biometric identity solutions, announced a remarkable 63% increase in transaction volume on its platform from August 2023 to August 2024. This surge reflects a growing…
Sage Therapeutics, Inc. (Nasdaq: SAGE) has unveiled a strategic reorganization initiative aimed at prioritizing the commercialization of ZURZUVAE® for postpartum depression while sharpening its focus on pipeline development, including the upcoming clinical study for dalzanemdor in Huntington’s Disease, slated for…
Artesunate AMIVAS, the first fully licensed treatment for severe malaria in Europe, is now available for purchase across Europe and the U.K. through Nordic Prime in Denmark. Approved by the European Commission and the U.K.’s Medicines and Healthcare products Regulatory…
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO), announced its fourth consecutive Platinum Award from The Asset ESG (Environmental, Social, and Governance) Corporate Awards. This recognition highlights the company’s dedication to sustainable…
Alnylam Submits Type II Variation to EMA for Vutrisiran in ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2024—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced the submission of a Type II Variation to the European Medicines Agency (EMA) for vutrisiran, an…
The Women’s Brain Foundation and Medscape Education Launch Learning Center on Sex and Gender in Brain Health The Women’s Brain Foundation (WBF), a leader in integrating sex- and gender-based research in healthcare since 2017, has partnered with Medscape Education, a…
